Finkelstein Thompson LLP Investigates Potentially Unfair Buyout of KYTHERA Biopharmaceuticals, Inc.

WASHINGTON--(BUSINESS WIRE)--Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of KYTHERA Biopharmaceuticals, Inc. (“Kythera” or the “Company”) (NasdaqGS: KYTH), concerning the Company’s proposed acquisition by Allergan plc. Under the terms of the proposal, KYTHERA shareholders will receive $75.00 in cash for each share of KYTHERA common stock they own. At least one analyst has set a high target price of $85.00 for KYTHERA shares. The entire transaction is valued at approximately $2.1 billion.